Related articles

In cancer care, adjusting care plans becomes crucial as a patient’s condition changes. With the advancement of modern care testing technologies, the care team can monitor the patient’s health status and response to care in real-time, adjusting the care plan promptly based on the testing data to achieve optimal outcomes. These testing data not only provide specific information regarding tumor progression but also help the care team understand the patient’s immune status, metabolic features, and other key indicators, thus enabling precise and personalized care.

In cancer care, developing a personalized care plan for each patient is crucial, especially during the initial diagnosis phase. This phase is not only the starting point for medical record collection and diagnosis but also a critical moment for determining the direction of future care. Scientific testing methods can help medical teams fully understand a patient’s health status, cancer risks, metabolic characteristics, and more, thereby establishing a personalized care baseline. These tests provide real-time data that serve as an important reference for future care adjustments.

Colorectal cancer (CRC) is one of the most prevalent cancers worldwide, with a high mortality rate. Among its complications, liver metastasis is one of the most common sites for distant spread. Once liver metastasis occurs, the prognosis for the patient significantly worsens. Traditional methods for monitoring colorectal cancer metastasis mostly rely on imaging techniques, such as CT or MRI, which, while helpful in visualizing the tumor, are often limited in detecting small metastases or early-stage changes. Therefore, early detection of liver metastasis and continuous monitoring of disease progression are crucial in formulating an optimal care plan for patients.

In the process of cancer care, advanced-stage patients often face challenges such as rapid disease progression and unstable treatment responses. For these patients, the need for dynamic monitoring is particularly urgent. Traditional monitoring methods often rely on imaging tests and biochemical markers, and the results may lag behind the actual changes in the patient’s condition. With the advancement of technology, modern testing techniques, such as RGCC’s Circulating Tumor Cell (CTC) testing, provide patients with more immediate and accurate disease assessments, helping healthcare providers adjust care plans promptly, improve treatment outcomes, and extend patients’ survival.

Cancer development is often the result of interactions between genetic and environmental factors. Understanding the genetic background of cancer is crucial for assessing individual risk, developing preventive strategies, and conducting early screenings.

Surgery is often the first step in the treatment of cancer patients. However, even when the surgery successfully removes the tumor, the risk of cancer recurrence still exists. Traditional imaging and histological tests can only detect significant changes when the tumor has grown or metastasized, making it impossible to capture the tiny remnants of cancer cells in time. This means that many patients may appear to be cancer-free after surgery, but potential cancer cells remain, leading to disease recurrence.

With advancements in tumor detection technology, liquid biopsy has emerged as a non-invasive method with immense potential in early tumor screening, metastasis monitoring, and treatment evaluation. Particularly, RGCC CTC (Circulating Tumor Cell) testing is gaining increasing importance in tumor care. This technology provides crucial information on tumor metastasis while simultaneously assessing the patient’s nutritional status, offering valuable insights for developing personalized care plans.